vs
Lantheus Holdings, Inc.(LNTH)とRevolve Group, Inc.(RVLV)の財務データ比較。上の社名をクリックして会社を切り替えられます
Lantheus Holdings, Inc.の直近四半期売上が大きい($406.8M vs $324.4M、Revolve Group, Inc.の約1.3倍)。Lantheus Holdings, Inc.の純利益率が高く(13.3% vs 5.7%、差は7.6%)。Revolve Group, Inc.の前年同期比売上増加率が高い(10.4% vs 4.0%)。Lantheus Holdings, Inc.の直近四半期フリーキャッシュフローが多い($81.4M vs $-13.3M)。過去8四半期でRevolve Group, Inc.の売上複合成長率が高い(9.5% vs 4.9%)
ランティウス・ホールディングスはグローバルな医療企業で、革新的な診断用造影剤や関連ソリューションの開発・製造・販売を事業の核としています。製品は腫瘍学、循環器学、泌尿器学などの分野に対応し、北米を中心に世界の主要市場で事業を展開しています。
Revolve Theatre Companyはテムズ河畔ヘンリーを拠点とする劇団で、政治的なテーマの作品やシェイクスピア劇を専門に制作・上演しており、オリバー・デンチ、ジョー・モリス、トム・スミスの3人が所有しています。
LNTH vs RVLV — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $406.8M | $324.4M |
| 純利益 | $54.1M | $18.6M |
| 粗利率 | 59.2% | 53.3% |
| 営業利益率 | 19.0% | 6.3% |
| 純利益率 | 13.3% | 5.7% |
| 売上前年比 | 4.0% | 10.4% |
| 純利益前年比 | 558.8% | 50.4% |
| EPS(希薄化後) | $0.86 | $0.27 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $406.8M | $324.4M | ||
| Q3 25 | $384.0M | $295.6M | ||
| Q2 25 | $378.0M | $309.0M | ||
| Q1 25 | $372.8M | $296.7M | ||
| Q4 24 | $391.1M | $293.7M | ||
| Q3 24 | $378.7M | $283.1M | ||
| Q2 24 | $394.1M | $282.5M | ||
| Q1 24 | $370.0M | $270.6M |
| Q4 25 | $54.1M | $18.6M | ||
| Q3 25 | $27.8M | $21.2M | ||
| Q2 25 | $78.8M | $10.2M | ||
| Q1 25 | $72.9M | $11.8M | ||
| Q4 24 | $-11.8M | $12.3M | ||
| Q3 24 | $131.1M | $11.0M | ||
| Q2 24 | $62.1M | $15.4M | ||
| Q1 24 | $131.1M | $10.9M |
| Q4 25 | 59.2% | 53.3% | ||
| Q3 25 | 57.9% | 54.6% | ||
| Q2 25 | 63.8% | 54.1% | ||
| Q1 25 | 63.8% | 52.0% | ||
| Q4 24 | 63.5% | 52.5% | ||
| Q3 24 | 63.9% | 51.2% | ||
| Q2 24 | 64.9% | 54.0% | ||
| Q1 24 | 65.4% | 52.3% |
| Q4 25 | 19.0% | 6.3% | ||
| Q3 25 | 11.4% | 7.1% | ||
| Q2 25 | 23.3% | 5.8% | ||
| Q1 25 | 27.4% | 5.0% | ||
| Q4 24 | 29.1% | 3.9% | ||
| Q3 24 | 35.3% | 5.0% | ||
| Q2 24 | 26.1% | 5.8% | ||
| Q1 24 | 28.8% | 3.4% |
| Q4 25 | 13.3% | 5.7% | ||
| Q3 25 | 7.2% | 7.2% | ||
| Q2 25 | 20.8% | 3.3% | ||
| Q1 25 | 19.6% | 4.0% | ||
| Q4 24 | -3.0% | 4.2% | ||
| Q3 24 | 34.6% | 3.9% | ||
| Q2 24 | 15.8% | 5.4% | ||
| Q1 24 | 35.4% | 4.0% |
| Q4 25 | $0.86 | $0.27 | ||
| Q3 25 | $0.41 | $0.29 | ||
| Q2 25 | $1.12 | $0.14 | ||
| Q1 25 | $1.02 | $0.16 | ||
| Q4 24 | $-0.18 | $0.18 | ||
| Q3 24 | $1.79 | $0.15 | ||
| Q2 24 | $0.88 | $0.21 | ||
| Q1 24 | $1.87 | $0.15 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $359.1M | $292.3M |
| 総負債低いほど良い | $568.7M | — |
| 株主資本純資産 | $1.1B | $512.5M |
| 総資産 | $2.2B | $765.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.52× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $359.1M | $292.3M | ||
| Q3 25 | $382.0M | $315.4M | ||
| Q2 25 | $695.6M | $310.7M | ||
| Q1 25 | $938.5M | $300.8M | ||
| Q4 24 | $912.8M | $256.6M | ||
| Q3 24 | $866.4M | $252.8M | ||
| Q2 24 | $757.0M | $244.7M | ||
| Q1 24 | $718.3M | $273.4M |
| Q4 25 | $568.7M | — | ||
| Q3 25 | $567.9M | — | ||
| Q2 25 | $566.8M | — | ||
| Q1 25 | $566.1M | — | ||
| Q4 24 | $565.3M | — | ||
| Q3 24 | $613.0K | — | ||
| Q2 24 | $563.2M | — | ||
| Q1 24 | $562.5M | — |
| Q4 25 | $1.1B | $512.5M | ||
| Q3 25 | $1.1B | $490.2M | ||
| Q2 25 | $1.2B | $468.6M | ||
| Q1 25 | $1.2B | $453.4M | ||
| Q4 24 | $1.1B | $437.8M | ||
| Q3 24 | $1.2B | $420.8M | ||
| Q2 24 | $1.0B | $405.8M | ||
| Q1 24 | $945.5M | $389.9M |
| Q4 25 | $2.2B | $765.0M | ||
| Q3 25 | $2.3B | $751.3M | ||
| Q2 25 | $2.1B | $722.9M | ||
| Q1 25 | $2.1B | $713.9M | ||
| Q4 24 | $2.0B | $665.5M | ||
| Q3 24 | $2.0B | $670.9M | ||
| Q2 24 | $1.9B | $657.8M | ||
| Q1 24 | $1.8B | $650.0M |
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.59× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $90.2M | $-10.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $81.4M | $-13.3M |
| FCFマージンFCF / 売上 | 20.0% | -4.1% |
| 設備投資強度設備投資 / 売上 | 2.2% | 1.0% |
| キャッシュ転換率営業CF / 純利益 | 1.67× | -0.55× |
| 直近12ヶ月FCF直近4四半期 | $354.1M | $48.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $90.2M | $-10.2M | ||
| Q3 25 | $105.3M | $11.8M | ||
| Q2 25 | $87.1M | $12.6M | ||
| Q1 25 | $107.6M | $45.1M | ||
| Q4 24 | $157.7M | $3.9M | ||
| Q3 24 | $175.1M | $9.1M | ||
| Q2 24 | $84.7M | $-24.7M | ||
| Q1 24 | $127.2M | $38.4M |
| Q4 25 | $81.4M | $-13.3M | ||
| Q3 25 | $94.7M | $7.5M | ||
| Q2 25 | $79.1M | $10.4M | ||
| Q1 25 | $98.8M | $43.4M | ||
| Q4 24 | $141.4M | $2.1M | ||
| Q3 24 | $159.3M | $8.0M | ||
| Q2 24 | $73.5M | $-25.7M | ||
| Q1 24 | $119.0M | $36.7M |
| Q4 25 | 20.0% | -4.1% | ||
| Q3 25 | 24.7% | 2.5% | ||
| Q2 25 | 20.9% | 3.4% | ||
| Q1 25 | 26.5% | 14.6% | ||
| Q4 24 | 36.1% | 0.7% | ||
| Q3 24 | 42.0% | 2.8% | ||
| Q2 24 | 18.7% | -9.1% | ||
| Q1 24 | 32.2% | 13.5% |
| Q4 25 | 2.2% | 1.0% | ||
| Q3 25 | 2.8% | 1.5% | ||
| Q2 25 | 2.1% | 0.7% | ||
| Q1 25 | 2.3% | 0.6% | ||
| Q4 24 | 4.2% | 0.6% | ||
| Q3 24 | 4.2% | 0.4% | ||
| Q2 24 | 2.8% | 0.4% | ||
| Q1 24 | 2.2% | 0.6% |
| Q4 25 | 1.67× | -0.55× | ||
| Q3 25 | 3.79× | 0.56× | ||
| Q2 25 | 1.11× | 1.24× | ||
| Q1 25 | 1.47× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | 1.34× | 0.83× | ||
| Q2 24 | 1.36× | -1.60× | ||
| Q1 24 | 0.97× | 3.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |